Giulia Fadda profile picture

Contact Information

Giulia Fadda, MD

Giulia Fadda

Associate Scientist, Neuroscience
Ottawa Hospital Research Institute
Neurologist, Division of Neurology, Department of Medicine
The Ottawa Hospital
Assistant Professor, Neurology, Department of Medicine
University of Ottawa

Research Interests

1. Multiple Sclerosis: use of advanced neuroimaging and molecular biology for the characterization of the mechanisms responsible for progressive brain damage, and develop tools for its early detection and monitoring in the clinical setting,

2. MOG antibody associated disease: characterization of the imaging, serum and cerebrospinal fluid markers associated with the spectrum of MOGAD clinical manifestations, define the processes behind the variability of clinical outcome and identify the most effective treatment strategies.

Brief Biography

Dr. Giulia Fadda is a neurologist at the Ottawa Hospital, Department of Medicine, assistant professor at the University of Ottawa, Faculty of Medicine and Associate Scientist in the Neuroscience Program at the Ottawa Hospital Research Institute.
She completed most of her clinical training in Italy, followed by a research fellowship in neuroimmunology at the University of Pennsylvania and a clinical-research fellowship in multiple sclerosis and neuroinflammatory disorders at McGill University.

Her research has contributed to characterize the features associated with onset of multiple sclerosis during childhood, to define the accuracy of the diagnostic criteria in this age group, and disclose early markers of brain damage through the use of advanced MRI techniques. She also contributed to the clinical, imaging and laboratory characterization of MOG antibody associated disease, and is involved in international initiatives aimed at improving the diagnosis and treatment of this condition.

Selected Publications

1. Fadda G., Flanagan E. P., Cacciaguerra L., Jitprapaikulsan J., Solla P., Zara P., Sechi E. (2022), Myelitis features and outcomes in CNS demyelinating disorders: Comparison between multiple sclerosis, MOGAD, and AQP4-IgG-positive NMOSD, Frontiers in Neurology, 13:1011579
PMID: 36419536, DOI: 10.3389/fneur.2022.1011579

2. Magliozzi R., Fadda G., Brown R., Bar-Or A., Howell O.W., Hamentener S., Marastoni D., Poli A., Nicholas R., Calabrese M., Monaco S., Reynolds R. (2022), Ependymal-in gradient of thalamic damage in progressive multiple sclerosis, Annals of Neurology
PMID: 35748636; DOI: 10.1002/ana.26448

3. Fadda G., Waters P., Woodhall M., Brown R.A., O’Mahony J, Castro D, Longoni G., Yeh E.A., Marrie R.A., Arnold D.L., Banwell B., Bar-Or A. (2022), Serum MOG-IgG in children meeting multiple sclerosis diagnostic criteria, Multiple Sclerosis Journal, 13524585221093789
PMID: 35581944; DOI: 10.1177/13524585221093789

4. Fadda G., Alves C.A., O'Mahony J., Castro D. A., Yeh E.A., Marrie R.A., Arnold D.L., Waters P., Bar-Or A., Vossough A., Banwell B. (2021), Comparison of Spinal Cord Magnetic Resonance Imaging Features Among Children With Acquired Demyelinating Syndromes, JAMA network open 4 (10), e2128871-e2128871
PMID: 34643718, DOI: 10.1001/jamanetworkopen.2021.28871

5. Fadda G., Armangue T., Hacohen Y., Chitnis T., Banwell B. (2021), Pediatric multiple sclerosis and antibody-associated demyelination: clinical, imaging and biological considerations for diagnosis and care, The Lancet Neurology 20 (2), 136-149
PMID: 33484648, DOI: 10.1016/S1474-4422(20)30432-4

6. Waters P.*, Fadda G.* (*equal contribution), Woodhall M., Irani S., O’Mahony J., Brown R.A., Castro D., Longoni G., Yeh E. A., Marrie R.A., Arnold D., Banwell B., Bar-Or A. (2020), on behalf of the Canadian Pediatric Demyelinating Disease Network, “Serial Anti–Myelin Oligodendrocyte Glycoprotein Antibody Analyses and Outcomes in Children With Demyelinating Syndromes”, JAMA neurology 77 (1), 82-93
PMID: 31545352, DOI: 10.1001/jamaneurol.2019.2940

7. Fadda G., Brown R.A., Magliozzi R., Shinoara R., Aubert-Broche B., O’Mahoney J., Banwell B., Marrie R.A., Yeh E.A., Collins D.L., Arnold D.L., Bar-Or A. (2019), on behalf of the Canadian Pediatric Demyelinating Disease Network, “A ‘surface-in’ gradient of damage evolves in pediatric multiple sclerosis”, Annals of neurology 85 (3), 340-351
PMID: 30719730, DOI: 10.1002/ana.25429

8. Fadda G, Brown RA, Longoni G, Castro D, O’Mahony J, Verhey LH, Branson HM, Waters P, Bar-Or A, Marrie RA, Yeh EA, Narayanan S, Arnold DL, Banwell B, on behalf of the Canadian Pediatric Demyelinating Disease Network (2018), “MRI and laboratory features and the performance of international criteria in the diagnosis of multiple sclerosis in children and adolescents: a prospective cohort study”, The Lancet Child & Adolescent Health 2 (3), 191-204
PMID: 30169254, DOI: 10.1016/S2352-4642(18)30026-9

Diseases, conditions and populations of interest

Research and clinical approaches